Stay updated on PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial
Sign up to get notified when there's something new on the PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial page.

Latest updates to the PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page has undergone significant content changes, particularly the removal of detailed study information regarding a Phase II trial for Pembrolizumab in BRCA-related Metastatic Breast Cancer, while retaining the mention of the study's location and the drug PEMBRACA.SummaryDifference49%
- Check16 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check24 days agoNo Change Detected
- Check60 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check74 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check81 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check96 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.1%
Stay in the know with updates to PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial page.